Relmada Therapeutics Stock (NASDAQ:RLMD)


ForecastOwnershipFinancialsChartTranscripts

Previous Close

$2.98

52W Range

$1.88 - $7.22

50D Avg

$3.37

200D Avg

$3.82

Market Cap

$86.00M

Avg Vol (3M)

$180.95K

Beta

0.41

Div Yield

-

RLMD Company Profile


Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

20

IPO Date

Jun 20, 2014

Website

RLMD Performance


RLMD Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-103.70M$-161.25M$-125.70M
Net Income$-98.79M$-157.04M$-125.75M
EBITDA$-103.70M$-156.44M$-124.45M
Basic EPS$-3.28$-5.30$-7.16
Diluted EPS$-3.28$-5.30$-7.16

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 10, 24 | 9:39 AM
Q2 24Aug 09, 24 | 6:25 AM
Q1 24May 08, 24 | 12:00 AM

Peer Comparison


TickerCompany
DICEDICE Therapeutics, Inc.
ENOBRenovaro Biosciences Inc.
CYTCyteir Therapeutics, Inc.
NUVBNuvation Bio Inc.
MGTADianthus Therapeutics, Inc.
PMVPPMV Pharmaceuticals, Inc.
FUSNFusion Pharmaceuticals Inc.
DYNDyne Therapeutics, Inc.
RVMDRevolution Medicines, Inc. Warrant
EWTXEdgewise Therapeutics, Inc.
IPSCCentury Therapeutics, Inc.
CSBRChampions Oncology, Inc.
GRPHLENZ Therapeutics, Inc.
NAMSNewAmsterdam Pharma Company N.V.
THRDThird Harmonic Bio, Inc.
NLTXNeurogene Inc.
CYTKCytokinetics, Incorporated
KRTXKaruna Therapeutics, Inc.
BCYCBicycle Therapeutics plc
PRDSPardes Biosciences, Inc.
STTKShattuck Labs, Inc.
RAPTRAPT Therapeutics, Inc.
ELYMEliem Therapeutics, Inc.